Nothing said here yet.
to join the conversation.
| POST LEONARD EDirector | Sell | 500 | $31.2K | Thu, Oct 15 |
| POST LEONARD EDirector | Sell | 500 | $30.8K | Thu, Oct 15 |
| POST LEONARD EDirector | Sell | 1,000 | $73.0K | Tue, Sep 15 |
| POST LEONARD EDirector | Sell | 1,000 | $74.5K | Fri, Aug 14 |
In October 2026, CG Oncology appointed Isabel Kalofonos as Chief Commercial Officer, tasking her with leading commercial strategy as the company prepares for the potential launch of its bladder cancer therapy cretostimogene grenadenorepvec.
CG Oncology stock has delivered very strong 1 year gains, yet the broader valuation checks and current pricing leave investors weighing how much of the story is already reflected in the share price.
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc.
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -28.57% and -59.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected fourth quarter 2026 Phase 3 BOND-003 Cohort C Study…
Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorable safety and tolerability in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancerDALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc.
Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology in 2010 PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc.
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.